- Details
- Christina Curtis shares insights from her work on breast and gastrointestinal cancers, discussing their potential application to prostate cancer. The focus of her discussion revolves around innovative strategies for defining biomarkers of therapy response using spatial proteomic approaches. Dr. Curtis describes how this new technology lets researchers examine the composition of tumor cells and the...
|
- Details
- Alicia Morgans hosts Sumit Subudhi to discuss underutilized therapies for metastatic castration-resistant prostate cancer (mCRPC). Dr. Subudhi expounds on the complexities of Sipuleucel-T and Radium-223, highlighting their benefits for maintaining patient quality of life. He clarifies that while these therapies do not reduce prostate-specific antigen (PSA) levels, they slow down cancer growth, exp...
|
- Details
- Asmaa El-Kenawi shares her research on the effects of nutrient availability in the tumor microenvironment as part of her Prostate Cancer Foundation (PCF) Young Investigator Award. Her work centers around understanding the dynamic interactions of cancer cells with immune cells, normal cells, and physical factors, like oxygen and pressure, and micronutrients within the cancerous environment. She aim...
|
- Details
- Alicia Morgans hosts a discussion with Rahul Aggarwal about his ongoing research on DLL3 targeting BiTE therapy. DLL3 is expressed in an aggressive form of prostate cancer known as neuroendocrine prostate cancer. Dr. Aggarwal's study focuses on using an immunotherapeutic approach to target DLL3, using a compound developed by Amgen that enhances immune response. With 40 patients already enrolled in...
|
- Details
- Rana McKay joins Alicia Morgans to discuss the RadiCaL trial, a study looking at metastatic kidney cancer and the use of radium in that population. The trial is a phase II trial, taking patients with renal cell carcinoma (RCC) with bone metastases and randomizing them 1:1 to receive radium with cabozantinib versus cabozantinib alone. The primary endpoint of RadiCaL is a reduction in symptomatic sk...
|
- Details
- Neil Bander joins Charles Ryan providing a historical perspective on radioligand therapy and the history of prostate-specific membrane antigen (PSMA) for prostate cancer treatment. Dr. Bander recounts his early work in radioligand therapy and how it has developed over the past two decades before discussing the current ongoing trials highlighting a single ascending dose trial and a multiple dose tr...
|
- Details
- Neeraj Agarwal delves into two ground-breaking studies, discussing the importance of ctDNA testing and the clinical implications of SPOP mutations in patients with metastatic prostate cancer. The first study, led by Dr. Kim Chi, demonstrates that ctDNA testing is a viable alternative to invasive tissue testing, particularly in detecting BRCA and ATM mutations. CtDNA tests showed impressive sensiti...
|
- Details
- Alicia Morgans and Edwin Posadas are joined in conversation at the 29th Annual Prostate Cancer Foundation (PCF) Retreat to discuss the influence PCF has had on the community and his research career. Dr. Posadas reflects on the honor of being named a PCF Young Investigator in 2010 and believes that being a part of the PCF allows young researchers to collaborate and innovate together to find solutio...
|
- Details
- Amy Moran joins Alicia Morgans in a discussion on the mechanisms of immunotherapy resistance in prostate cancer patients, and how androgens or the androgen receptor (AR) contribute. Amy Moran received a Prostate Cancer Foundation Young Investigator Award for this research which aims to reveal how androgens and AR activity regulate human T cell function and immunotherapy resistance and may reveal n...
|
- Details
- In this conversation, Lorelei Mucci and Alicia Morgans discuss highlights from the 29th Annual Prostate Cancer Foundation (PCF) Retreat, including the immunogenomic landscape of African-American prostate cancer patients, a presentation by Tamara Lotan as part of the session titled the Impact of Molecular and Genomic Factors on Prostate Cancer Disease Etiology and Health Disparities. They also disc...
|
